Publicaciones en colaboración con investigadores/as de University of Kansas Cancer Center (1)

2022

  1. Efficacy and safety of itacitinib versus placebo in combination with corticosteroids for initial treatment of acute graft-versus-host disease (GRAVITAS-301): a randomised, multicentre, double-blind, phase 3 trial

    The Lancet Haematology, Vol. 9, Núm. 1, pp. e14-e25